Skip to main content
Premium Trial:

Request an Annual Quote

Ben Bulkley, John Radak, Bernd Brust, Kelli Richard, David Wellis

Premium
Invitrogen last week said in an SEC filing that Ben Bulkley, its senior vice president of commercial operations, and John Radak, its finance and principal accounting officer, will leave the company at the end of January.
 
Bulkley will be replaced by Bernd Brust, Invitrogen’s general manager and vice president of European operations. Brust will be responsible for sales strategies, customer relations, and identifying avenues for customer growth, the company said.
 
Radak will be replaced by Kelli Richard, who has served as corporate controller at Invitrogen and as vice president and controller at Gateway.
 
David Wellis was appointed CEO of DNA sample storage company GenVault in mid-December, the company said last week.
 
Before coming to GenVault Wellis was vice president of functional genomics at Axon Instruments.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.